TY - JOUR
T1 - Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women
T2 - A randomized, double-blind, crossover study
AU - Kwang, Kon Koh
AU - Seung, Hwan Han
AU - Shin, Mi Seung
AU - Jeong, Yeal Ahn
AU - Lee, Yonghee
AU - Eak, Kyun Shin
PY - 2005/7
Y1 - 2005/7
N2 - Aims: We have previously reported that lower doses of hormone therapy (L-HT) and tibolone have different effects on markers of cardiovascular disease when compared with conventional doses of HT. The objective was to compare the effects of L-HT and tibolone on lipid profile, vasodilation, and factors associated with inflammation and haemostasis. Methods and results: Forty-one women received a combination of micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg vs. tibolone 2.5 mg alone daily in random order during 2 months with 2 months washout period. When compared with L-HT, tibolone significantly reduced total cholesterol (P < 0.001), triglyceride (P < 0.001), HDL cholesterol (P < 0.001) levels, and triglyceride/HDL cholesterol ratios (P = 0.004) except total cholesterol/HDL cholesterol ratios. Tibolone improved flow-mediated response to hyperaemia from baseline values (P < 0.001) by a similar magnitude to L-HT. L-HT and tibolone did not increase high-sensitivity C-reactive protein relative to baseline values. L-HT reduced antithrombin III from baseline values (P = 0.037), compared with tibolone showing no changes. However, there was no difference between either. In contrast, tibolone increased pro-thrombin fragment 1+2 (F1 + 2) from baseline values (P = 0.002), compared with L-HTshowing no changes. Tibolone significantly reduced plasma plasminogen activator inhibitor type 1 (PAI-1) antigen levels from baseline values (P = 0.004), compared with L-HTshowing no changes. The effects of L-HT and tibolone on F1+2 and PAI-1 were significantly different (P = 0.045 and P = 0.008, respectively). Conclusion: Both tibolone and L-HT improved flow-mediated response by a similar magnitude and did not significantly increase high-sensitivity C-reactive protein. However, tibolone significantly reduced PAI-1, but increased F1+2 more than L-HT.
AB - Aims: We have previously reported that lower doses of hormone therapy (L-HT) and tibolone have different effects on markers of cardiovascular disease when compared with conventional doses of HT. The objective was to compare the effects of L-HT and tibolone on lipid profile, vasodilation, and factors associated with inflammation and haemostasis. Methods and results: Forty-one women received a combination of micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg vs. tibolone 2.5 mg alone daily in random order during 2 months with 2 months washout period. When compared with L-HT, tibolone significantly reduced total cholesterol (P < 0.001), triglyceride (P < 0.001), HDL cholesterol (P < 0.001) levels, and triglyceride/HDL cholesterol ratios (P = 0.004) except total cholesterol/HDL cholesterol ratios. Tibolone improved flow-mediated response to hyperaemia from baseline values (P < 0.001) by a similar magnitude to L-HT. L-HT and tibolone did not increase high-sensitivity C-reactive protein relative to baseline values. L-HT reduced antithrombin III from baseline values (P = 0.037), compared with tibolone showing no changes. However, there was no difference between either. In contrast, tibolone increased pro-thrombin fragment 1+2 (F1 + 2) from baseline values (P = 0.002), compared with L-HTshowing no changes. Tibolone significantly reduced plasma plasminogen activator inhibitor type 1 (PAI-1) antigen levels from baseline values (P = 0.004), compared with L-HTshowing no changes. The effects of L-HT and tibolone on F1+2 and PAI-1 were significantly different (P = 0.045 and P = 0.008, respectively). Conclusion: Both tibolone and L-HT improved flow-mediated response by a similar magnitude and did not significantly increase high-sensitivity C-reactive protein. However, tibolone significantly reduced PAI-1, but increased F1+2 more than L-HT.
KW - Endothelial function
KW - Haemostasis
KW - Hormone therapy
KW - Inflammation
KW - Lower doses
KW - Tibolone
UR - http://www.scopus.com/inward/record.url?scp=25444448995&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehi311
DO - 10.1093/eurheartj/ehi311
M3 - Article
C2 - 15872028
AN - SCOPUS:25444448995
SN - 0195-668X
VL - 26
SP - 1362
EP - 1368
JO - European Heart Journal
JF - European Heart Journal
IS - 14
ER -